沙库巴曲缬沙坦联合达格列净治疗冠心病合并心力衰竭患者的临床疗效

doi:10.3969/j.issn.1671-7171.2025.08.012

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1245 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the clinical efficacy of sacubitril valsartan combined with dapagliflozin in the treatment of coronary heart disease (CHD) complicated with heart failure (HF). 【Methods】 A total of 82 patients with CHD complicated with HF admitted to our hospital from September 2020 to September 2023 were prospectively selected and divided into the observation group and the control group using a random number table method, with 41 patients in each group. The control group was treated with sacubitril valsartan, while the observation group was treated with sacubitril valsartan combined with dapagliflozin. The two groups were compared in terms of clinical efficacy, cardiac function indicators [left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF) and 6-minute walking distance (6MWD)], laboratory indicators [brain natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), nitric oxide (NO), endothelin-1 (ET-1)], 1-year readmission rate due to HF, and incidence of adverse reactions. 【Results】The total effective rate of the observation group was higher than that of the control group, with a statistically significant difference (P<0.05). After treatment, LVEF and 6MWD in both groups were higher than those before treatment, while LVEDD and LVESD were lower than those before treatment; LVEF and 6MWD in the observation group were higher than those in the control group, and LVEDD and LVESD were lower than those in the control group, with statistically significant differences (P<0.05). After treatment, the serum levels of BNP, hs-CRP, and ET-1 in both groups were lower than those before treatment, and the observation group had lower levels than the control group; the serum NO level in both groups was higher than that before treatment, and the observation group had a higher level than the control group, with statistically significant differences (P<0.05). The readmission rate due to HF in the observation group was lower than that in the control group, with a statistically significant difference (P=0.022). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】Sacubitril valsartan combined with dapagliflozin has a good clinical efficacy in the treatment of CHD complicated with HF. It improves patients' cardiac function and vascular endothelial function, inhibits inflammatory response, reduces the readmission rate of patients, and has good safety.

Key words： Coronary Disease Heart Failure Valsartan Drug Therapy, Combination

Received: 29 February 2024

PACS:

R541.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Xiangna

Cite this article:

LI Xiangna. Clinical Efficacy of Sacubitril Valsartan Combined with Dapagliflozin in the Treatment of Coronary Heart Disease Complicated with Heart Failure[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(8): 1335-1338.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.08.012 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I8/1335

[1] ZHAO G L, ZHANG H Y, WANG Y, et al. Effects of levocarnitine on cardiac function, urinary albumin, hs-CRP, BNP, and troponin in patients with coronary heart disease and heart failure[J].Hellenic J Cardiol,2020,61(2):99-102.
[2] 孟雅杰, 陈嘉怡, 李敬超, 等. 沙库巴曲缬沙坦钠片治疗冠心病合并慢性心力衰竭的疗效及对患者心功能与炎性因子水平的影响[J].海南医学, 2023,34(5):621-624.
[3] HUSSAIN M, ATIF M, BABAR M, et al. Comparison of efficacy and safety profile of empagliflozin versus dapagliflozin as add on therapy in type 2 diabetic patients[J].J Ayub Med Coll Abbottabad,2021,33(4):593-597.
[4] 王晶, 刘易婷, 刘哲. 达格列净和维格列汀对糖尿病合并冠心病老年患者血糖、血管内皮功能及心功能的影响[J].陕西医学杂志, 2022,51(12):1581-1584.
[5] 李雪博, 范燕宾, 杜睿, 等. 达格列净、恩格列净及卡格列净在心肌梗死后预防心力衰竭患者的临床研究[J].中国临床药理学杂志, 2023,39(22):3204-3208.
[6] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 冠心病诊断与治疗指南[J].中华心血管病杂志, 2007,35(3):195-206.
[7] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志, 2014,42(2):98-122.
[8] 顾丽萍, 胡菁, 严蜀华. 美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效及对患者心功能、心肌重塑和炎症因子的影响[J].中国老年学杂志, 2017,37(1):89-91.
[9] 吴景煌, 黄修献, 陈天德. 沙库巴曲缬沙坦治疗心力衰竭临床观察[J].中国药业, 2023,32(5):104-107.
[10] SCOTT D SOLOMON, JOHN J V MCMURRAY, BRIAN CLAGGETT, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction[J].N Engl J Med,2022,387(12):1089-1098.
[11] 蔡月娣, 梁碧, 黄彩英. 达格列净治疗老年2型糖尿病患者的疗效及对患者胰岛β细胞功能、心功能的影响[J].海南医学, 2023,34(2):190-193.
[12] ZHOU Q L, PAN L L, XUE R C, et al. The anti-microbial peptide LL-37/CRAMP levels are associated with acute heart failure and can attenuate cardiac dysfunction in multiple preclinical models of heart failure[J].Theranostics,2020,10(14):6167-6181.
[13] XU W D, TAO H X, HU D, et al. Serum BNP level expression in pediatric patients with ventricular septal defects and its relation with cardiac function and heart failure[J].Minerva Pediatr (Torino),2022,74(2):132-135.
[14] PAKHTUSOV N N, IUSUPOVA A O,PRIVALOVA E V, et al. Endothelial dysfunction and inflammation in patients with non-obstructive coronary arteries[J].Kardiologiia,2021,61(1):52-58.